Status: Recruiting
A Study on Efficacy, Safety and Immunogenicity of 9MW0311 in Postmenopausal Women With Osteoporosis
This study is a multicenter, randomized, double-blinded, parallel-group Phase III clinical study to compare the clinical efficacy, safety, and immunogenicity of 9MW0311 and Prolia® in Chinese postmenopausal women with osteoporosis at high risk for fracture.
Participants needed: 278
Trial details
Phase: Phase 3Age: 50-80Biological sex: FemaleType: InterventionalSponsor: Mabwell (Shanghai) Bioscience Co., Ltd.Updated: Feb 3, 2025Locations: 1
Eligibility criteria
Women who can walk freely (≥50 and ≤80 years); [+3]
Bone/metabolic disease [+23]